The Use of DHEA in Women With Premature Ovarian Failure

Early Phase 1

Withdrawn

• Conditions: Premature Ovarian Failure
• Interventions: Drug: DHEA

• Registration Number: NCT01129947
• Lead Sponsor: Virginia Center for Reproductive Medicine

Brief Summary

DHEA supplementation has been used in women with infertility and diminished ovarian reserve. There is a small report in 5 women with POF that benefited from the use of DHEA over several months. The investigators aim to evaluate further the use of DHEA in women with Premature ovarian failure (POF).

Detailed Description

Not available

Study Timeline

• Study Start: 2010-05
• Study First Submitted: 2010-05-23
• Study First Submitted QC: 2010-05-24
• Study First Posted: 2010-05-25
• Status Verified: 2013-01
• Primary Completion: 2013-01
• Study Completion: 2013-01
• Last Update Submitted: 2013-01-26
• Last Update Posted: 2013-01-29

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

• women with POF

Exclusion Criteria

• women without ovaries

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
DHEA	DHEA	-

Primary Outcome Measures

Name	Time	Method
The Use of DHEA in Women With Premature Ovarian Failure	3 years	The following outcomes will be evaluated: FSH, AMH, estradiol, ovarian volume, antral follicle count, pregnancy in women seeking to conceive

Trial Locations

Locations (1)

Virginia Center for Reproductive Medicine; 🇺🇸 Reston, Virginia, United States